🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

John Hunting

Wake Forest University

ORCID: 0000-0002-4066-4763
Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Impact of comorbidity burden on immune-related adverse events and survival among older adults with cancer on immunotherapy.”.

Impact of comorbidity burden on immune-related adverse events and survival among older adults with cancer on immunotherapy.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.12061
N/A
0DataRank · unranked
4 citations

Heidi D. Klepin, Beverly J. Levine, Alexander M. Quattlebaum, Chance H. Bloomer, Lara M. Khoury +5 more

Time to treatment initiation in a retrospective cohort of patients with advanced lung cancer treated with an immune checkpoint inhibitor.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e21199
N/A
0DataRank · unranked
0 citations

Andrew T. Faucheux, Greg Russell, Christopher Duckworth, John Hunting, Catherine A. Elko +5 more

Palliative care consultation and end-of-life outcomes in a retrospective cohort of patients treated with immune checkpoint inhibitors.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.6577
N/A
0DataRank · unranked
0 citations

Andrew T. Faucheux, Alexander M. Quattlebaum, Catherine A. Elko, John Hunting, Lara M. Khoury +4 more

Tumor-intrinsic CDC42BPB confers resistance to anti-PD-1 immune checkpoint blockade in breast cancer

Molecular Therapy(2024)10.1016/j.ymthe.2024.07.021
N/A
0DataRank · unranked
6 citations

Kerui Wu, Shih-Ying Wu, Abhishek Tyagi, Eleanor C. Smith, John Hunting +4 more